Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31975311,globule size,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),nm,160,7126,DB01200,Bromocriptine
,31975311,zeta potential,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),mv,-,7127,DB01200,Bromocriptine
,31975311,zeta potential,"The optimized formulation exhibited a mean globule size of 160 ± 6.5 nm, zeta potential of - 20.4 ± 1.23 mV, and drug content of 99.45 ± 1.9%.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),mv,20.4,7128,DB01200,Bromocriptine
,31975311,enhancement ratio (ER),"Ex vivo permeation studies across rat skin exhibited a significant enhancement in permeation, i.e., enhancement ratio (ER) of ~ 7.4 and 5.86 for BCM-NE and BCM-NE gel, respectively, when compared with aqueous BCM suspension gel.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),,7.4,7129,DB01200,Bromocriptine
,31975311,enhancement ratio (ER),"Ex vivo permeation studies across rat skin exhibited a significant enhancement in permeation, i.e., enhancement ratio (ER) of ~ 7.4 and 5.86 for BCM-NE and BCM-NE gel, respectively, when compared with aqueous BCM suspension gel.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),,5.86,7130,DB01200,Bromocriptine
,31975311,AUC0-t,"The AUC0-t for BCM-NE gel and BCM suspension was found to be 562.54 ± 77.55 and 204.96 ± 51.93 ng/ml h, respectively.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),[ng] / [h·ml],562.54,7131,DB01200,Bromocriptine
,31975311,AUC0-t,"The AUC0-t for BCM-NE gel and BCM suspension was found to be 562.54 ± 77.55 and 204.96 ± 51.93 ng/ml h, respectively.","Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),[ng] / [h·ml],204.96,7132,DB01200,Bromocriptine
,31975311,relative bioavailability (%F),The relative bioavailability (%F) of BCM was shown to be enhanced 274% by BCM-NE gel.,"Bromocriptine Nanoemulsion-Loaded Transdermal Gel: Optimization Using Factorial Design, In Vitro and In Vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975311/),%,274,7133,DB01200,Bromocriptine
,23266466,zeta potential,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),m,40.3,19967,DB01200,Bromocriptine
,23266466,loading capacity,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,37.8,19968,DB01200,Bromocriptine
,23266466,entrapment efficiency,"These NPs had a mean size (161.3 ± 4. 7 nm), zeta potential (+40.3 ± 2.7 mV), loading capacity (37.8% ± 1.8%) and entrapment efficiency (84.2% ± 3.5%).","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19969,DB01200,Bromocriptine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.47,19970,DB01200,Bromocriptine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.69,19971,DB01200,Bromocriptine
,23266466,brain/blood ratio,"The brain/blood ratio of 0.47 ± 0.04, 0.69 ± 0.031, and 0.05 ± 0.01 for BRC solution (i.n.), BRC loaded CS NPs (i.n.) and (i.v.) respectively, at 0.5h are suggestive of direct nose to brain transport bypassing the blood-brain barrier.","Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),,0.05,19972,DB01200,Bromocriptine
,23266466,drug targeting index,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,6.3,19973,DB01200,Bromocriptine
,23266466,direct transport percentage,The drug targeting index and direct transport percentage for BRC loaded CS NPs following i.n. route were 6.3 ± 0.8 and 84.2% ± 1.9%.,"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266466/),%,84.2,19974,DB01200,Bromocriptine
,403149,invasion half-life,The mean invasion half-life was 0.5 hours (range 0.32-1.12 hours).,Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,0.5,20609,DB01200,Bromocriptine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,1.4-6.2,20610,DB01200,Bromocriptine
,403149,elimination half-lives,"The mean elimination half-lives ranged from 1.4-6.2 hours for the alpha-phase and from 13 to 50 hours for the beta-phase, the longest values being observed with bromocriptine.",Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/403149/),h,13 to 50,20611,DB01200,Bromocriptine
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB01200,Bromocriptine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],555,80371,DB01200,Bromocriptine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],702,80372,DB01200,Bromocriptine
,3173919,peak plasma levels,"For the same vaginal doses, the mean (+/- SEM) peak plasma levels were 555 +/- 164 pg/mL at 12 +/- 0.6 hours, 702 +/- 252 pg/mL at 11.2 +/- 0.9 hours, and 1055 +/- 220 pg/mL at 10.7 +/- 1.7 hours, respectively.",Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3173919/),[pg] / [ml],1055,80373,DB01200,Bromocriptine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.42,115958,DB01200,Bromocriptine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.82,115959,DB01200,Bromocriptine
,3956565,half-life,This fast release process was followed by slow clearance with a half-life of 16 days.,Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956565/),d,16,123278,DB01200,Bromocriptine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.96,134211,DB01200,Bromocriptine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.73,134212,DB01200,Bromocriptine
,24655115,brain:blood ratios,"The brain:blood ratios of 0.96 ± 0.05 > 0.73 ± 0.15 > 0.25 ± 0.05 of BRC-loaded CS NPs (i.n.) > BRC solution (i.n.) > BRC-loaded CS NPs (intravenous), respectively, at 0.5 h indicated direct nose-to-brain transport bypassing blood-brain barrier.","Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655115/),,0.25,134213,DB01200,Bromocriptine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB01200,Bromocriptine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB01200,Bromocriptine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB01200,Bromocriptine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB01200,Bromocriptine
,16379666,peak,"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [l],0.28,200605,DB01200,Bromocriptine
,16379666,t(max),"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,0.46,200606,DB01200,Bromocriptine
,16379666,AUC(last),"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [h·l],0.39,200607,DB01200,Bromocriptine
,16379666,terminal elimination half-life,"The peak of DHEC was 0.28 +/- 0.22 microg/l, the t(max) 0.46 +/- 0.26 h, the AUC(last) 0.39 +/- 0.41 microg/l.h and the terminal elimination half-life 3.50 +/- 2.27 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,3.50,200608,DB01200,Bromocriptine
,16379666,peak,"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [l],5.63,200609,DB01200,Bromocriptine
,16379666,t(max),"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,1.04,200610,DB01200,Bromocriptine
,16379666,AUC(last),"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),[μg] / [h·l],13.36,200611,DB01200,Bromocriptine
,16379666,terminal elimination half-life,"The peak of 8'-OH-DHEC was 5.63 +/- 3.34 microg/l, the t(max) 1.04 +/- 0.66 h, the AUC(last) 13.36 +/- 5.82 microg/l.h and the terminal elimination half-life 3.90 +/- 1.07 h.",Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379666/),h,3.90,200612,DB01200,Bromocriptine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],2.10,215026,DB01200,Bromocriptine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.96,215027,DB01200,Bromocriptine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.05,215028,DB01200,Bromocriptine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],1.94,215029,DB01200,Bromocriptine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.91,215030,DB01200,Bromocriptine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.81,215031,DB01200,Bromocriptine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,16.4,222423,DB01200,Bromocriptine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.541,222424,DB01200,Bromocriptine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,28.0,222425,DB01200,Bromocriptine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],2.00,222426,DB01200,Bromocriptine
,19908205,t(1/2),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),min,24.0,222427,DB01200,Bromocriptine
,19908205,V(ss),"In rats, the estimated pharmacokinetic parameters (i.e., t(1/2), CL, and V(ss)) of HAL when administered with DAL and BCT were t(1/2) = 16.4 min, V(ss) = 0.541 L/kg for HAL, t(1/2) = 28.0 min, V(ss) = 2.00 L/kg for DAL, and t(1/2) = 24.0 min, V(ss) = 0.106 L/kg for BCT.","Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19908205/),[l] / [kg],0.106,222428,DB01200,Bromocriptine
,8050122,IGF-I,Basal mean IGF-I value for all 11 patients was 716 +/- 96 micrograms/l.,Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8050122/),[μg] / [l],716,257580,DB01200,Bromocriptine
,4041556,absolute bioavailability,"The results indicated that oral doses of bromocriptine were rapidly, though incompletely (32-40 per cent), absorbed, but underwent extensive first-pass metabolism, resulting in an absolute bioavailability of only 6 per cent.",Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041556/),%,6,263926,DB01200,Bromocriptine
,4041556,bioavailability,"The bioavailability increased to approximately 22 per cent in rats pretreated with the hepatic microsome inhibitor proadifen, thus suggesting the liver as the principal site of biotransformation.",Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041556/),%,22,263927,DB01200,Bromocriptine
